Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 76Neoplasm Metastasis 8Metastatic Castration Resistant Prostate Cancer 5Breast Neoplasms 5Neoplasms 3Metastatic Castration-Resistant Prostate Cancer 3Prostatic Neoplasms, Castration-Resistant 2Prostate Cancer Metastatic 2Castration-resistant Prostate Cancer 2Carcinoma, Non-Small-Cell Lung 2Salivary Glands Tumors 1Pharmacogenetic Study 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Newly Diagnosed Oligometastatic Prostate Cancer 1Metastatic Hormone Refractory Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Hyperaldosteronism 1Colorectal Neoplasms 1Advanced Cancer 1

Interventions

enzalutamide 4Abiraterone Acetate 2radium Ra 223 dichloride 1dactolisib 1abiraterone 1VT-464 1Prednisone 1NVP-BKM120 1Flutamide 1Crizotinib 1Control Groups 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Castration-resistant Prostate Cancer × Abiraterone Acetate × Clear all
NCT02025010 2025-04-15

Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
60 enrolled 17 charts
Genitourinary

Castration-resistant Prostate Cancer

NCT02429193 2020-01-13

BARRIER-P

University Health Network, Toronto

Phase 2 Completed
16 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡